Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268419 | 0.83 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL21508358 | 0.81 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5074166 | 0.81 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL38664535 | 0.80 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL13858200 | 0.80 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL23293452 | 0.80 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL3246700 | 0.78 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL1855362 | 0.77 | CHRM2 (0.53) | SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL28140496 | 0.77 | MEN1 (0.46) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL11623491 | 0.76 | CYP2D6 (0.57) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | claimed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | claimed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | SLC6A4 173/4885SLC6A2 474/4885SLC6A3 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.